The Leader in Tolnaftate Technology for More Than 30 Years

By Michael J. DiMeglio

The **Tetra Corporation** is the leader in tolnaftate pharmaceutical technology. Tetra's long history of innovation began more than 30 years ago with the research to develop, and ultimately patent, Soluble Tolnaftate[1] in 1989. Today, Tetra provides safe and clinically effective doctor-dispensed topical treatments, skin conditioners and dietary supplements with a guarantee that supports the practice of podiatric medicine. Tetra's commitment goes even further, as George A. Cioe PhD (hc), President and CEO states, "Our policy at every level of our company is to act in a way that ensures that doctors and staff never have an issue due to their dispensing of our products." To make certain that Tetra remains unequaled in customer service, Dr. Cioe also explains, "We maintain a

George A. Cioe, Ph.D. (h.c.) President and CEO

Tetra insures that their brands are exclusively doctor-dispensed.

well-staffed call center with seasoned representatives trained to address callers' questions in one call. In addition, our national sales force attends over 90 podiatric medical conferences annually in support of podiatric medicine."

The Tetra Corporation was founded on three key strategic elements: 1) Tetra's patented technology; 2) ensuring that their brands are exclusively doctor-dispensed; 3) and backing their pharmaceuticals with the first, un-

conditional, patient-direct, money-back guarantee in medicine.

Tetra's brands include Formula 7® Solution, Formula 7® Rapid MicroGel™, Formula 3®, FungiFoam®, Clean-

Tetra's long history of innovation began more than 30 years ago with the research to develop, and ultimately patent, Soluble Tolnaftate1 in 1989.

Sweep®, Kamea® 20, Kamea G®, and CoLig-10™. Formula 7®, our most recent innovation, is the only paraben-free Soluble Tolnaftate[1] antifungal microemulsion fortified with cosmetic ingredients and bactericidal agents. The oil phase is comprised of the jojoba oil with the Soluble Tolnaftate[1] and tea tree oil to fortify the microemulsion with antifungal, antiseptic, germicidal and antibacterial properties. The water phase contains N-acetyl-l-cysteine (NAC) and urea: urea to hydrate, soften, and open keratin for better drug penetration; NAC to increase the flux of tolnaftate through the keratin to the site of involvement and provide bactericidal properties. Tetra has a patent pending with the U.S. Patent and Trademark Office for Formula 7® Solution and Formula 7® Rapid MicroGel™.

Tetra is a proud supporter of podiatric medicine with a nationwide salesforce and a well-staffed call center. Further, Tetra is a frequent exhibitor at medical conferences nationwide. When you call Tetra, a person answers the phone to give you, the medical practitioner, the best service possible with a "one call resolution policy."

Call Tetra today at 800-826-0479 or click here and you are sure to be impressed!

[1] US Patent #4,810,498 and US Patent #RE 36-253

Formula 7®—The Solution and Formula 7® Rapid Micro-Gel™ Patent Pending

|4|